Published in BMJ on February 06, 1993
Alcohol and airways function in health and disease. Alcohol (2007) 1.53
Alcohol up-regulates TLR2 through a NO/cGMP dependent pathway. Alcohol Clin Exp Res (2009) 0.88
Sleep-related breathing disorders. 7. Sleep and breathing problems in general medicine. Thorax (1995) 0.75
Alcohol not a predictor of peripheral oedema in chronic bronchitis. BMJ (1993) 0.75
Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia. Lancet (1986) 5.65
Does right ventricular function predict survival in patients with chronic obstructive lung disease? Thorax (1988) 1.33
Renal sodium retention and vasopressin induced kaliuresis in ethanol anaesthetised rats. Acta Endocrinol (Copenh) (1985) 1.09
Eucapnia and hypercapnia in patients with chronic airflow limitation. The role of the upper airway. Am Rev Respir Dis (1990) 1.06
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Particulate air pollution and acute health effects. Lancet (1995) 9.26
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Transient hypoxaemia during sleep in chronic bronchitis and emphysema. Lancet (1979) 4.85
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53
Ambient particle inhalation and the cardiovascular system: potential mechanisms. Environ Health Perspect (2001) 3.49
Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol (2001) 3.38
The sleep hypopnea syndrome. Am Rev Respir Dis (1988) 3.31
Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med (2001) 3.19
Clinical value of polysomnography. Lancet (1992) 3.19
Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med (1996) 3.04
Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med (1999) 2.98
Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea/Hypopnea syndrome. Am J Respir Crit Care Med (1999) 2.77
Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 2.68
Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome. Lancet (1994) 2.68
Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J (2000) 2.63
Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax (2000) 2.62
Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro. Thorax (1996) 2.58
Self-reported use of CPAP and benefits of CPAP therapy: a patient survey. Chest (1996) 2.58
Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Thorax (1997) 2.47
Evaluation of a portable device for diagnosing the sleep apnoea/hypopnoea syndrome. Eur Respir J (2003) 2.42
Telomere shortening in smokers with and without COPD. Eur Respir J (2006) 2.27
Ultrafine particles. Occup Environ Med (2001) 2.23
Accuracy sensitivity to carboxyhemoglobin, and speed of response of the Hewlett-Packard 47201A ear oximeter. Am Rev Respir Dis (1979) 2.17
Factors impairing daytime performance in patients with sleep apnea/hypopnea syndrome. Arch Intern Med (1992) 2.15
Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis (1997) 2.15
Adverse health effects of PM10 particles: involvement of iron in generation of hydroxyl radical. Occup Environ Med (1996) 2.12
Neck soft tissue and fat distribution: comparison between normal men and women by magnetic resonance imaging. Thorax (1999) 2.12
CT measurements of lung density in life can quantitate distal airspace enlargement--an essential defining feature of human emphysema. Am Rev Respir Dis (1988) 2.06
Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? Am J Respir Crit Care Med (1999) 2.02
The current dilemma with spirometric inclusion criteria for asthma drug trials. Ann Allergy Asthma Immunol (1997) 2.02
Sleep apnoea: clinical importance and facilities for investigation and treatment in the UK. Addendum to the 1993 Royal College of Physicians Sleep Apnoea report. J R Coll Physicians Lond (1999) 2.01
The effect of nonvisible sleep fragmentation on daytime function. Am J Respir Crit Care Med (1997) 1.98
Hypothesis: does COPD have an autoimmune component? Thorax (2003) 1.98
Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax (2004) 1.93
Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax (2005) 1.92
Increased inflammation and intracellular calcium caused by ultrafine carbon black is independent of transition metals or other soluble components. Occup Environ Med (2000) 1.88
Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol (1999) 1.87
Role of transcription factors in inflammatory lung diseases. Thorax (1998) 1.85
Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax (1994) 1.85
Uvulopalatopharyngoplasty may compromise nasal CPAP therapy in sleep apnea syndrome. Am J Respir Crit Care Med (1996) 1.84
Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med (1996) 1.83
Diagnosis of pulmonary emphysema by computerised tomography. Lancet (1984) 1.80
Randomised placebo controlled trial of daytime function after continuous positive airway pressure (CPAP) therapy for the sleep apnoea/hypopnoea syndrome. Thorax (1998) 1.77
Short-term inflammatory responses following intratracheal instillation of fine and ultrafine carbon black in rats. Inhal Toxicol (1999) 1.76
Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. BMJ (1990) 1.73
Measurement of CT lung density in patients with chronic asthma. Eur Respir J (1997) 1.71
Pulmonary hypertension and right ventricular function in patients with COPD. Chest (1988) 1.67
Cognitive function in the sleep apnea/hypopnea syndrome (SAHS). Sleep (2000) 1.66
Irregular breathing and hypoxaemia during sleep in chronic stable asthma. Lancet (1982) 1.65
Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am J Respir Crit Care Med (1999) 1.63
Hypoxic ventilatory response decreases during sleep in normal men. Am Rev Respir Dis (1982) 1.62
The effect of oxygenation on sleep quality in chronic bronchitis and emphysema. Am Rev Respir Dis (1982) 1.62
Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med (2000) 1.61
Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med (1998) 1.61
Bronchodilatation and the site of airway resistance in severe chronic bronchitis. Thorax (1979) 1.60
Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J (2008) 1.59
Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis (1983) 1.58
Clinical features of the sleep apnoea/hypopnoea syndrome. Q J Med (1989) 1.56
Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J Neurol Neurosurg Psychiatry (2006) 1.55
The effect of sleep fragmentation on daytime function. Am J Respir Crit Care Med (1996) 1.55
Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax (1992) 1.54
Free radical activity of PM10: iron-mediated generation of hydroxyl radicals. Environ Health Perspect (1997) 1.53
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
Under reporting of sleepiness and driving impairment in patients with sleep apnoea/hypopnoea syndrome. J Sleep Res (1997) 1.51
Increased calcium influx in a monocytic cell line on exposure to ultrafine carbon black. Eur Respir J (2000) 1.51
Respiration during sleep in normal man. Thorax (1982) 1.49
Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis (1982) 1.48
Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax (1996) 1.47
Evaluation of Biox IIA ear oximeter. Thorax (1985) 1.46
An investigation of the role of glutathione in increased epithelial permeability induced by cigarette smoke in vivo and in vitro. Am J Respir Crit Care Med (1994) 1.42
Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax (2001) 1.42
Does arousal frequency predict daytime function? Eur Respir J (1998) 1.41
The effect of age, sex, obesity and posture on upper airway size. Eur Respir J (1997) 1.41
Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.39
Breathing patterns during sleep in patients with nocturnal asthma. Thorax (1987) 1.39
Activation of NF-kappaB by PM(10) occurs via an iron-mediated mechanism in the absence of IkappaB degradation. Toxicol Appl Pharmacol (2000) 1.36
Effect of continuous positive airway pressure on sleep architecture in the sleep apnea-hypopnea syndrome: a randomized controlled trial. Am J Respir Crit Care Med (2001) 1.36
Can psychological factors help us to determine adherence to CPAP? A prospective study. Eur Respir J (2004) 1.36
The effect of posture on upper airway dimensions in normal subjects and in patients with the sleep apnea/hypopnea syndrome. Am Rev Respir Dis (1991) 1.35
Effect of sleep deprivation on overnight bronchoconstriction in nocturnal asthma. Thorax (1986) 1.34
Does right ventricular function predict survival in patients with chronic obstructive lung disease? Thorax (1988) 1.33
Spectral oscillations of RR intervals in sleep apnoea/hypopnoea syndrome patients. Eur Respir J (2003) 1.33
Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest (1999) 1.31
The role of tumor necrosis factor in increased airspace epithelial permeability in acute lung inflammation. Am J Respir Cell Mol Biol (1995) 1.29
Comparison of nose and face mask CPAP therapy for sleep apnoea. Thorax (1998) 1.29
Family studies in patients with the sleep apnea-hypopnea syndrome. Ann Intern Med (1995) 1.28
Partners of patients with sleep apnoea/hypopnoea syndrome: effect of CPAP treatment on sleep quality and quality of life. Thorax (2001) 1.27
Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax (1991) 1.26
Sleep-disordered breathing and upper airway size in pregnancy and post-partum. Eur Respir J (2006) 1.25
Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J (1991) 1.24
Induction of gamma-glutamylcysteine synthetase by cigarette smoke is associated with AP-1 in human alveolar epithelial cells. FEBS Lett (1996) 1.23
Management of obstructive sleep apnoea/hypopnoea syndrome. Lancet (1994) 1.23
Frequency of EEG arousals from nocturnal sleep in normal subjects. Sleep (1995) 1.23
Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax (1997) 1.23
Sexual influence on the control of breathing. J Appl Physiol Respir Environ Exerc Physiol (1983) 1.22
Tumour necrosis factor-alpha (-308) gene polymorphism in obstructive sleep apnoea-hypopnoea syndrome. Eur Respir J (2005) 1.21
Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax (1994) 1.18
Review of the prescription of domiciliary long term oxygen therapy in Scotland. Thorax (1995) 1.18